Une nouvelle classe de molécules hypolipémiantes : les ligands de SCAP

Thierry Grand-Perret; Anne Bouillot; Marc Issandou

doi:10.1051/medsci/20021867659

Accueil

Tous les numéros

Volume 18 / Numéro 6-7 (Juin–Juillet 2002)

Med Sci (Paris), 18 6-7 (2002) 659-661

Références

Accès gratuit

Numéro		Med Sci (Paris) Volume 18, Numéro 6-7, Juin–Juillet 2002


Page(s)		659 - 661
Section		Le Magazine : Nouvelles
DOI		https://doi.org/10.1051/medsci/20021867659
Publié en ligne		15 juin 2002

Ansell BJ, Watson KE, Fogelman AM. An evidence-based assessment of the NCEP adult treatment panel II guidelines. National cholesterol education program. JAMA 1999; 282 : 2051–7. [Google Scholar]
Kovanen PT, Schneider WJ. Regulation of the low density lipoprotein (B/E) receptor. Adv Vasc Biol 1999; 5 : 165–85. [Google Scholar]
Hua X, Nohturfft A, Goldstein JL, Brown MS. Protein sterol resistance in CHO cells traced to point mutation in SREBP cleavage-activating protein. Cell 1996; 87 : 415–22. [Google Scholar]
Matsuda M, Korn BS, Hammer RE, et al. SREBP cleavage-activating protein (SCAP) is required for increased lipid synthesis in liver induced by cholesterol deprivation and insulin elevation. Genes Dev 2001; 15 : 1206–16. [Google Scholar]
Sakai J, Nohturfft A, Goldstein JL, Brown MS. Cleavage of sterol regulatory element-binding proteins (SREBPs) at site-1 requires interaction with SREBP cleavage-activating protein. Evidence from in vivo competition studies. J Biol Chem 1998; 273 : 5785–93. [Google Scholar]
Briggs MR, Yokoyama C, Wang X, Brown MS, Goldstein JL. Nuclear protein that binds sterol regulatory element of low density lipoprotein receptor promoter. J Biol Chem 1993; 268 : 14490–6. [Google Scholar]
Grand-Perret T, Bouillot A, Perrot A, Commans S, Walker M, Issandou M. SCAP ligands are potent new lipid-lowering drugs. Nat Med 2001; 7 :1332–8. [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.

[1] Ansell BJ, Watson KE, Fogelman AM. An evidence-based assessment of the NCEP adult treatment panel II guidelines. National cholesterol education program. JAMA 1999; 282 : 2051–7. [Google Scholar]

[2] Kovanen PT, Schneider WJ. Regulation of the low density lipoprotein (B/E) receptor. Adv Vasc Biol 1999; 5 : 165–85. [Google Scholar]

[3] Hua X, Nohturfft A, Goldstein JL, Brown MS. Protein sterol resistance in CHO cells traced to point mutation in SREBP cleavage-activating protein. Cell 1996; 87 : 415–22. [Google Scholar]

[4] Matsuda M, Korn BS, Hammer RE, et al. SREBP cleavage-activating protein (SCAP) is required for increased lipid synthesis in liver induced by cholesterol deprivation and insulin elevation. Genes Dev 2001; 15 : 1206–16. [Google Scholar]

[5] Sakai J, Nohturfft A, Goldstein JL, Brown MS. Cleavage of sterol regulatory element-binding proteins (SREBPs) at site-1 requires interaction with SREBP cleavage-activating protein. Evidence from in vivo competition studies. J Biol Chem 1998; 273 : 5785–93. [Google Scholar]

[6] Briggs MR, Yokoyama C, Wang X, Brown MS, Goldstein JL. Nuclear protein that binds sterol regulatory element of low density lipoprotein receptor promoter. J Biol Chem 1993; 268 : 14490–6. [Google Scholar]

[7] Grand-Perret T, Bouillot A, Perrot A, Commans S, Walker M, Issandou M. SCAP ligands are potent new lipid-lowering drugs. Nat Med 2001; 7 :1332–8. [Google Scholar]